Detection of novel therapeutic targets and biomarkers via identification of beneficial oral/ gut bacteria to enhance the response of PD1/PD-L1 blockade therapy in oral cancer patients

• Project/Area Number: 24K13070
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 57060:Surgical dentistry-related
• Research Institution: Yamaguchi University
• Principal Investigator: Ferdous Tarannum 山口大学, 医学部, 特別医学研究員 (70647932)
• Co-Investigator(Kenkyū-buntansha): 原田 耕志 広島都市学園大学, 健康科学部, 教授(移行) (60253217)
• Project Period (FY): 2024-04-01 – 2027-03-31
• Project Status: Granted (Fiscal Year 2024)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2026: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000); Fiscal Year 2025: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2024: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
• Keywords: oral microbiomes / gut bacteria / PD -1/PD-L1

Outline of Research at the Start

Samples from anti-PD-1 therapy responder and non-responder patients/mice will be examined to identify beneficial bacteria for therapy. These bacteria will be used in combination with anti-PD-1 therapy to enhance its efficacy, and to develop anti-PD-1-based biomarkers and treatment strategy for OSCC.